Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenström macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Brutons tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Future research should focus on identifying targeted agents against activating mutations and long-term data for currently available novel agents should be critically evaluated, both in treatment-naïve and in relapsed/refractory settings.

Original languageEnglish (US)
Pages (from-to)1143-1156
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume15
Issue number10
DOIs
StatePublished - Oct 3 2015

Fingerprint

Waldenstrom Macroglobulinemia
Lymphoma
Mutation
Therapeutics
Non-Hodgkin's Lymphoma
Immunoglobulin M
B-Lymphocytes
Safety
Proteins

Keywords

  • bendamustine
  • BTK inhibitors
  • HDAC inhibitors
  • immunomodulators
  • mTOR inhibitors
  • MYD88L265P
  • PI3K/AKT/PKC inhibitors
  • proteasome inhibitors
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. / Chakraborty, Rajshekhar; Kapoor, Prashant; Ansell, Stephen Maxted; Gertz, Morie.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 10, 03.10.2015, p. 1143-1156.

Research output: Contribution to journalArticle

@article{47c2f60cbe5042e0b2f6a26f65ab8d20,
title = "Emerging therapeutic options for Waldenstr{\"o}m macroglobulinemia/lymphoplasmacytic lymphoma",
abstract = "Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenstr{\"o}m macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenstr{\"o}m macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenstr{\"o}m macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Brutons tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenstr{\"o}m macroglobulinemia/lymphoplasmacytic lymphoma. Future research should focus on identifying targeted agents against activating mutations and long-term data for currently available novel agents should be critically evaluated, both in treatment-na{\"i}ve and in relapsed/refractory settings.",
keywords = "bendamustine, BTK inhibitors, HDAC inhibitors, immunomodulators, mTOR inhibitors, MYD88L265P, PI3K/AKT/PKC inhibitors, proteasome inhibitors, Waldenstr{\"o}m macroglobulinemia",
author = "Rajshekhar Chakraborty and Prashant Kapoor and Ansell, {Stephen Maxted} and Morie Gertz",
year = "2015",
month = "10",
day = "3",
doi = "10.1586/14737140.2015.1071668",
language = "English (US)",
volume = "15",
pages = "1143--1156",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

AU - Chakraborty, Rajshekhar

AU - Kapoor, Prashant

AU - Ansell, Stephen Maxted

AU - Gertz, Morie

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenström macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Brutons tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Future research should focus on identifying targeted agents against activating mutations and long-term data for currently available novel agents should be critically evaluated, both in treatment-naïve and in relapsed/refractory settings.

AB - Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenström macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Brutons tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Future research should focus on identifying targeted agents against activating mutations and long-term data for currently available novel agents should be critically evaluated, both in treatment-naïve and in relapsed/refractory settings.

KW - bendamustine

KW - BTK inhibitors

KW - HDAC inhibitors

KW - immunomodulators

KW - mTOR inhibitors

KW - MYD88L265P

KW - PI3K/AKT/PKC inhibitors

KW - proteasome inhibitors

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84942521202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942521202&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1071668

DO - 10.1586/14737140.2015.1071668

M3 - Article

VL - 15

SP - 1143

EP - 1156

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -